NCT06176690RecruitingPhase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Source: ClinicalTrials.gov · Last updated 2 Oct 2026

Brief summary (registry, in English)

This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to treat cancer. Antibodies bind to foreign substances, and T cells are infection-fighting white blood cells that can kill tumor cells. Both approaches have shown promise but have not been sufficient to cure most patients. In prior studies, an antibody targeting CD30, a protein found on some T cells and cancer cells, was joined to T cells through gene transfer to create CD30.CAR T cells. Another study showed encouraging responses using CD30.CAR T cells made from a patient's own blood and returned to the same patient (autologous cells). In an ongoing study, patients have been treated with CD30.CAR T cells derived from healthy donors (allogeneic cells), allowing use of banked cells without individualized manufacturing. This approach has shown promising clinical activity with no safety concerns to date. In this study, investigators are evaluating CD30.CAR-EBVST cells modified with an additional molecule called C7R, which has been shown in laboratory studies to enhance anti-cancer effects. The study aims to assess the safety and effectiveness of these allogeneic, banked C7R-modified CD30.CAR-EBVST cells and determine whether they may help treat lymphoma. As an added safety measure, the modified T cells include a marker called iC9. If significant side effects occur, patients may receive rimiducid, which can eliminate the infused T cells. Rimiducid is not yet FDA approved but has been tested in patients without significant side effects.

Status (registry): Recruiting
Phase (registry): Phase 1
Study type: Interventional
Enrollment: 90 (estimated)
First submitted: 11 Dec 2023
Start date: 27 Oct 2025
Primary completion date: 27 Jul 2028
Lead sponsor: Baylor College of Medicine
Diseases: Diffuse large B-cell lymphoma, Hodgkin lymphoma, Childhood cancers
NCT number: NCT06176690

What you commit to

Study type: Interventional · Phase 1
Planned participants: 90
From 27 Oct 2025 to the primary completion date, 27 Jul 2028
2 sites in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Received an investigational cell therapy or vaccine within the past 6 weeks.
Received an investigational small molecule drug within the past 2 weeks.
Received anti-CD30 antibody-based therapy within the previous 4 weeks.
Current use of systemic corticosteroids at a dose equivalent to or higher than 10 mg/day of prednisone.

Other illness

History of hypersensitivity reactions to murine protein-containing products.
Active significant, uncontrolled bacterial, viral or fungal infection.
Symptomatic cardiac disease (NYHA Class III or IV disease).

Other

Pregnant or lactating.
Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).

Who the study is looking for

Diagnosis and clinical course falling into one of the following categories:
- Hodgkin lymphoma
- CD30+ aggressive B-cell lymphoma
- ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma
- ALK-positive anaplastic T cell lymphoma
CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.
Age 12 to 75.
Bilirubin less than or equal to 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin less than or equal to 3 times the upper limit of normal).
AST less than 3 times the upper limit of normal.
Estimated GFR \> 70 mL/min.
Pulse oximetry of \> 90% on room air
Karnofsky or Lansky score of \> 60%.
Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.
Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.

Age in the registry: 12 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Houston Methodist Hospital Coordinator of this site? Confirm its status	Houston	United States	Recruiting
Texas Children's Hospital Coordinator of this site? Confirm its status	Houston	United States	Not yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.